Latest Maintenance therapy Stories
Today, during the 41st Annual Meeting & Exhibition of the American Association for Dental Research (AADR), held in conjunction with the 36th Annual Meeting of the Canadian Association for Dental Research, an abstract titled "Periodontal Therapy Reduces Hospitalizations and Medical Care Costs in Diabetics" to determine if periodontal treatment was associated with the number of hospitalizations and cost of medical care among diabetics with periodontal disease.
Biological agents may play an important role in maintaining remission in Crohn's disease, according to two new studies in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.
Discovery may lead to a new treatment.
Inflammatory bowel disease is a chronic recurrent disease, which mainly consists of ulcerative colitis and Crohn's disease, and whose causes are as yet unclear.
Humira Will Retain its Status as Decision Resources' Clinical Gold Standard for Crohn's Disease Through 2017, According to a New Report from Decision Resources WALTHAM, Mass., Jan.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO(TM) (mesalamine) extended-release capsules 0.375 g.
More Patients Switched to Mesalamine Granules Maintained Remission Versus Placebo (78 percent versus 59 percent) Salix Pharmaceuticals, Ltd. Adam C. Derbyshire Senior Vice President and Chief Financial Officer or G.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that 1.5 g mesalamine granules once-daily maintained remission versus placebo in ulcerative colitis (UC) patients who switched from another 5-ASA product (78 percent of relapse-free subjects vs. 59 percent (P less than 0.001)).
- A poem in which the author retracts something said in an earlier poem.